TLC Earns Highest Ranking in Corporate Governance Evaluation Six Years in a RowDownload
TLC is the only listed biotech company to achieve the elite status every year
TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, today announced that it has been ranked in the Top 5% in Corporate Governance Evaluation amongst all Taiwan Stock Exchange Corporation (TWSE) and Taipei Exchange (TPEx) listed companies in the sixth annual evaluation, becoming the only biotech company to have received this status for six consecutive years.
Evaluation indicators include protecting shareholder rights and interests, treating shareholders equitably, enhancing board composition and operation, increasing information transparency, and putting corporate social responsibility into practice. In the sixth annual evaluation, bonus points were given for disclosure of items including transfer of information, salary and remuneration information and security risks. All 901 TWSE- and 699 TPEx-listed companies were evaluated; the two groups were then separately ranked and categorized into seven brackets of Top 5%, 6% to 20%, 21% to 35%, 36% to 50%, 51% to 65%, 66% to 80%, and 81% to 100%. Among all 1,600 companies, TLC was the only biotech company to have remained in the Top 5% since the establishment of the evaluation system, once again solidifying its status as a benchmark for companies in the biotech landscape.